Develops cell-permeating peptide therapeutics to treat cancer and other diseases by modulating intracellular protein-protein interactions.
Aileron Therapeutics, Inc. is a clinical-stage oncology company based in Boston, Massachusetts, specializing in developing advanced chemoprotection therapies. Central to its pipeline is ALRN-6924, currently undergoing rigorous clinical evaluation across multiple trials. These include Phase 1 trials for solid tumors and lymphoma, Phase 2a trials for peripheral T-cell lymphoma, and Phase 1 trials targeting acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Additionally, the company is conducting Phase 1b trials to explore ALRN-6924 in combination with cytarabine (Ara-C) for MDS, and in combination with palbociclib for tumors with MDM2 amplifications and p53-mutated small cell lung cancer.
Originally known as Renegade Therapeutics, Inc., the company rebranded as Aileron Therapeutics, Inc. in 2007. Founded in 2001, Aileron operates under strategic license agreements with esteemed institutions like the Dana-Farber Cancer Institute and Harvard College, highlighting its commitment to colllaborative research and development. Additionally, the company maintains a partnership with Umicore Precious Metals Chemistry USA, LLC, further supporting its innovative approach to advancing cancer therapies.
Aileron Therapeutics continues to push the boundaries of oncology treatment with a strong focus on enhancing patient outcomes through its pioneering chemoprotection platform. With a dedication to scientific excellence and a robust pipeline of novel therapies, Aileron remains poised to make significant strides in addressing critical unmet needs in cancer care.